Israel’s BioLineRx (see here previously) has reported positive results in the Phase 3 trial of its Motixafortide treatment in combination with G-CSF for multiple myeloma. The treatment demonstrated improvement from five-fold to 14-fold compared to the control.

https://en.globes.co.il/en/article-biolinerx-soars-on-positive-phase-3-blood-cancer-trial-results-1001347840

https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-positive-top-line-results-genesis-phase-3